[go: up one dir, main page]

WO2009048101A1 - アミド化合物 - Google Patents

アミド化合物 Download PDF

Info

Publication number
WO2009048101A1
WO2009048101A1 PCT/JP2008/068369 JP2008068369W WO2009048101A1 WO 2009048101 A1 WO2009048101 A1 WO 2009048101A1 JP 2008068369 W JP2008068369 W JP 2008068369W WO 2009048101 A1 WO2009048101 A1 WO 2009048101A1
Authority
WO
WIPO (PCT)
Prior art keywords
amide compound
formula
disclosed
analgesic
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/068369
Other languages
English (en)
French (fr)
Inventor
Masakuni Kori
Mitsunori Kouno
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40549244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2009048101(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to JP2009537023A priority Critical patent/JPWO2009048101A1/ja
Priority to AU2008311727A priority patent/AU2008311727A1/en
Priority to CN2008801198900A priority patent/CN101981010A/zh
Priority to MX2010003918A priority patent/MX2010003918A/es
Priority to EA201070451A priority patent/EA201070451A1/ru
Priority to EP08836955A priority patent/EP2199282A4/en
Priority to BRPI0818366 priority patent/BRPI0818366A2/pt
Priority to US12/681,854 priority patent/US20100234389A1/en
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to CA2702171A priority patent/CA2702171A1/en
Publication of WO2009048101A1 publication Critical patent/WO2009048101A1/ja
Priority to TN2010000148A priority patent/TN2010000148A1/fr
Priority to IL204970A priority patent/IL204970A0/en
Priority to MA32749A priority patent/MA31759B1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　本発明の目的は、ＦＡＡＨ阻害作用を有し、鎮痛剤として有用な新規縮合環化合物を提供することである。本発明は、式（Ｉ）： ［式中の各記号は明細書に記載の通りである。］ で示される化合物またはその塩に関する。
PCT/JP2008/068369 2007-10-10 2008-10-09 アミド化合物 Ceased WO2009048101A1 (ja)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CA2702171A CA2702171A1 (en) 2007-10-10 2008-10-09 Amide compound
EP08836955A EP2199282A4 (en) 2007-10-10 2008-10-09 amide
AU2008311727A AU2008311727A1 (en) 2007-10-10 2008-10-09 Amide compound
CN2008801198900A CN101981010A (zh) 2007-10-10 2008-10-09 酰胺化合物
MX2010003918A MX2010003918A (es) 2007-10-10 2008-10-09 Compuesto de amida.
EA201070451A EA201070451A1 (ru) 2007-10-10 2008-10-09 Амидные соединения
BRPI0818366 BRPI0818366A2 (pt) 2007-10-10 2008-10-09 Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
JP2009537023A JPWO2009048101A1 (ja) 2007-10-10 2008-10-09 アミド化合物
US12/681,854 US20100234389A1 (en) 2007-10-10 2008-10-09 Amide compound
TN2010000148A TN2010000148A1 (en) 2007-10-10 2010-04-05 Amide compound
MA32749A MA31759B1 (fr) 2007-10-10 2010-04-08 Compose amide
IL204970A IL204970A0 (en) 2007-10-10 2010-04-08 Amide compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007264381 2007-10-10
JP2007-264381 2007-10-10

Publications (1)

Publication Number Publication Date
WO2009048101A1 true WO2009048101A1 (ja) 2009-04-16

Family

ID=40549244

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/068369 Ceased WO2009048101A1 (ja) 2007-10-10 2008-10-09 アミド化合物

Country Status (21)

Country Link
US (2) US20090163508A1 (ja)
EP (1) EP2199282A4 (ja)
JP (1) JPWO2009048101A1 (ja)
KR (1) KR20100064381A (ja)
CN (1) CN101981010A (ja)
AR (1) AR068764A1 (ja)
AU (1) AU2008311727A1 (ja)
BR (1) BRPI0818366A2 (ja)
CA (1) CA2702171A1 (ja)
CL (1) CL2008002998A1 (ja)
CO (1) CO6270225A2 (ja)
CR (1) CR11358A (ja)
DO (1) DOP2010000104A (ja)
EA (1) EA201070451A1 (ja)
IL (1) IL204970A0 (ja)
MA (1) MA31759B1 (ja)
MX (1) MX2010003918A (ja)
PE (1) PE20090815A1 (ja)
TN (1) TN2010000148A1 (ja)
TW (1) TW200924778A (ja)
WO (1) WO2009048101A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117014A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 トリアジン誘導体
WO2011078369A1 (ja) * 2009-12-25 2011-06-30 持田製薬株式会社 新規アリールウレア誘導体
WO2011136308A1 (ja) * 2010-04-28 2011-11-03 アステラス製薬株式会社 泌尿器疼痛を伴う疾患の予防又は治療剤
WO2011136307A1 (ja) * 2010-04-28 2011-11-03 アステラス製薬株式会社 夜間頻尿の予防又は治療剤
US8222425B2 (en) 2007-10-10 2012-07-17 Novartis Ag Organic compounds and their uses
JP2013518046A (ja) * 2010-01-25 2013-05-20 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US9688664B2 (en) 2010-05-03 2017-06-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007323193A1 (en) * 2006-11-20 2008-05-29 Glenmark Pharmaceuticals S.A. Acetylene derivatives as Stearoyl CoA Desaturase inhibitors
CL2008002998A1 (es) * 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
AU2010223919B2 (en) 2009-03-13 2016-03-31 Les Laboratoires Servier Methods and compositions for cell-proliferation-related disorders
DK2448582T3 (en) 2009-06-29 2017-07-17 Agios Pharmaceuticals Inc QUINOLIN-8 SULPHONAMIDE DERIVATIVES WITH ANTICANCER ACTIVITY
CA2793835C (en) 2009-10-21 2021-07-20 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
US20120225097A1 (en) * 2009-11-12 2012-09-06 Hawryluk Natalie A Piperazinecarboxamide derivative useful as a modulator of fatty acid amide hydrolase (faah)
US20130150346A1 (en) 2010-01-08 2013-06-13 Quest Ventures Ltd. Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain
FR2974729B1 (fr) * 2011-05-02 2013-04-19 Servier Lab Nouvelle association entre le 4-{3-[cis-hexahydrocyclopenta[c]pyrrol-2(1h)-yl]propoxy}benzamide et un inhibiteur de l'acetylcholinesterase et les compositions pharmaceutiques qui la contiennent
CA3088328A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use in therapy
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
JP2014521651A (ja) * 2011-07-28 2014-08-28 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
NZ722582A (en) 2012-01-06 2018-02-23 Agios Pharmaceuticals Inc Methods of preparing 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{ [2-(trifluoromethyl)pyridin-4-yl]amino} -1,3,5-triazin-2-yl)amino]propan-2-ol
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
AU2013331626B2 (en) 2012-10-15 2018-08-02 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CN105492435B (zh) 2013-07-11 2018-06-29 安吉奥斯医药品有限公司 作为idh2突变体抑制剂的化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EP3019480B1 (en) 2013-07-11 2020-05-06 Agios Pharmaceuticals, Inc. 2,4- or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
MA44392B1 (fr) 2015-06-11 2023-10-31 Agios Pharmaceuticals Inc Procédés d'utilisation d'activateurs de la pyruvate kinase
JP7033061B2 (ja) 2015-10-15 2022-03-09 アジオス ファーマシューティカルズ， インコーポレイテッド 悪性腫瘍を処置するため組合せ療法
MA71411A (fr) 2015-10-15 2025-04-30 Les Laboratoires Servier Polythérapie pour le traitement de tumeurs malignes
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501680A (ja) * 1996-06-29 1999-02-09 サムジン ファーマシューチカル カンパニー，リミテッド ピペラジン誘導体及びその製造方法
US20030092734A1 (en) 2000-03-27 2003-05-15 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
WO2004007495A1 (ja) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited ピロロピリジン誘導体およびその用途
WO2006054652A1 (ja) * 2004-11-18 2006-05-26 Takeda Pharmaceutical Company Limited アミド化合物
WO2007020888A1 (ja) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited 脳・神経細胞保護剤および睡眠障害治療薬
WO2007100610A2 (en) * 2006-02-23 2007-09-07 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP9602489A3 (en) * 1995-01-11 1998-01-28 Samjin Pharm Co Ltd Piperazine derivatives, process for producing them and pharmaceutical compositions containing them
EP1051176B1 (en) * 1998-01-27 2006-11-22 Aventis Pharmaceuticals Inc. SUBSTITUTED OXOAZAHETEROCYCLYL FACTOR Xa INHIBITORS
AU8066701A (en) * 2000-07-20 2002-02-05 Neurogen Corp Capsaicin receptor ligands
WO2003011220A2 (en) * 2001-07-31 2003-02-13 The Scripps Research Institute Animal model for fatty acid amide-related neurobehaviors
US20040063726A1 (en) * 2002-02-08 2004-04-01 Artman Linda D Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same
JPWO2004002531A1 (ja) * 2002-06-26 2005-10-27 小野薬品工業株式会社 血管の収縮または拡張による疾患治療剤
WO2004044169A2 (en) * 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
CL2008002998A1 (es) * 2007-10-10 2009-11-20 Takeda Pharmaceuticals Co Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11501680A (ja) * 1996-06-29 1999-02-09 サムジン ファーマシューチカル カンパニー，リミテッド ピペラジン誘導体及びその製造方法
US20030092734A1 (en) 2000-03-27 2003-05-15 The Scripps Research Institute Inhibitors of fatty acid amide hydrolase
WO2004007495A1 (ja) 2002-07-11 2004-01-22 Takeda Pharmaceutical Company Limited ピロロピリジン誘導体およびその用途
WO2006054652A1 (ja) * 2004-11-18 2006-05-26 Takeda Pharmaceutical Company Limited アミド化合物
WO2007020888A1 (ja) 2005-08-12 2007-02-22 Takeda Pharmaceutical Company Limited 脳・神経細胞保護剤および睡眠障害治療薬
WO2007100610A2 (en) * 2006-02-23 2007-09-07 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FASEB JOURNAL, vol. 18, 2004, pages 1580
NATURE, vol. 414, 2001, pages 209
See also references of EP2199282A4

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9169224B2 (en) 2004-12-30 2015-10-27 Janssen Pharmaceutica Nv Piperazinyl and piperidinyl ureas as modulators of fatty acid amide hydrolase
US8222425B2 (en) 2007-10-10 2012-07-17 Novartis Ag Organic compounds and their uses
WO2010117014A1 (ja) * 2009-04-08 2010-10-14 武田薬品工業株式会社 トリアジン誘導体
WO2011078369A1 (ja) * 2009-12-25 2011-06-30 持田製薬株式会社 新規アリールウレア誘導体
JP2013518046A (ja) * 2010-01-25 2013-05-20 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
WO2011136308A1 (ja) * 2010-04-28 2011-11-03 アステラス製薬株式会社 泌尿器疼痛を伴う疾患の予防又は治療剤
WO2011136307A1 (ja) * 2010-04-28 2011-11-03 アステラス製薬株式会社 夜間頻尿の予防又は治療剤
JPWO2011136308A1 (ja) * 2010-04-28 2013-07-22 アステラス製薬株式会社 泌尿器疼痛を伴う疾患の予防又は治療剤
US9688664B2 (en) 2010-05-03 2017-06-27 Janssen Pharmaceutica Nv Modulators of fatty acid amide hydrolase

Also Published As

Publication number Publication date
EP2199282A4 (en) 2011-04-27
TW200924778A (en) 2009-06-16
CA2702171A1 (en) 2009-04-16
DOP2010000104A (es) 2010-05-15
JPWO2009048101A1 (ja) 2011-02-24
IL204970A0 (en) 2010-11-30
TN2010000148A1 (en) 2011-11-11
CR11358A (es) 2010-07-12
AU2008311727A1 (en) 2009-04-16
US20100234389A1 (en) 2010-09-16
AR068764A1 (es) 2009-12-02
PE20090815A1 (es) 2009-07-20
CO6270225A2 (es) 2011-04-20
EA201070451A1 (ru) 2010-10-29
CN101981010A (zh) 2011-02-23
MA31759B1 (fr) 2010-10-01
BRPI0818366A2 (pt) 2015-04-07
AU2008311727A2 (en) 2010-05-06
MX2010003918A (es) 2010-08-04
EP2199282A1 (en) 2010-06-23
KR20100064381A (ko) 2010-06-14
CL2008002998A1 (es) 2009-11-20
US20090163508A1 (en) 2009-06-25

Similar Documents

Publication Publication Date Title
WO2009048101A1 (ja) アミド化合物
WO2009028629A1 (ja) 複素環化合物およびその用途
WO2009028655A1 (ja) 複素環化合物およびその用途
WO2009025358A1 (ja) 複素環化合物およびその用途
WO2009019015A8 (en) Novel herbicides
WO2007125547A3 (en) Novel process for statins and its pharmaceutically acceptable salts thereof
WO2011113798A3 (en) Inhibitors of semicarabazide - sensitive amine oxidase
WO2007109080A3 (en) Deuterated hepatitis c protease inhibitors
WO2009030469A8 (en) Fungicidal 2-alkylthio-2-quinolinyloxy-acetamide deritvatives
EP1844003A4 (en) NEW BIAROMATIC COMPOUNDS AS INHIBITORS OF THE P2X7 RECEPTOR
MY156319A (en) Spiroheterocyclic n-oxypiperidines as pesticides
WO2010063700A3 (en) Novel pyrazole-4 -n-alkoxycarboxamides as microbiocides
WO2008102908A1 (ja) ハロアルキルスルホンアニリド誘導体
WO2009024342A3 (en) Novel microbiocides
WO2006127932A3 (en) Purification of cinacalcet
WO2008123469A1 (ja) ６員環アミド化合物およびその用途
WO2008106047A3 (en) Carbamate compounds
WO2009051244A1 (ja) 複素環化合物
WO2005087724A3 (en) Sulphonylpyrroles as hdac inhibitors
WO2008153154A1 (ja) 環状化合物、フォトレジスト基材及びフォトレジスト組成物
WO2008151828A3 (en) Novel microbiocides
WO2008143668A3 (en) Indoleamine-2, 3-dioxygenase-2
WO2008136385A1 (ja) アミド化合物およびその用途
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
GB201305247D0 (en) Amide Compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880119890.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08836955

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2197/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 584368

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008836955

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008311727

Country of ref document: AU

Ref document number: 2010040554

Country of ref document: EG

ENP Entry into the national phase

Ref document number: 1001071

Country of ref document: KE

WWE Wipo information: entry into national phase

Ref document number: 2009537023

Country of ref document: JP

Ref document number: 204970

Country of ref document: IL

Ref document number: 11752

Country of ref document: GE

Ref document number: 12010500770

Country of ref document: PH

ENP Entry into the national phase

Ref document number: 20107007855

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2702171

Country of ref document: CA

Ref document number: 10041380

Country of ref document: CO

Ref document number: 201011358

Country of ref document: CR

Ref document number: MX/A/2010/003918

Country of ref document: MX

Ref document number: CR2010-011358

Country of ref document: CR

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: DZP2010000226

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 2008311727

Country of ref document: AU

Date of ref document: 20081009

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 201070451

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: a201004150

Country of ref document: UA

WWE Wipo information: entry into national phase

Ref document number: PI 2010001529

Country of ref document: MY

ENP Entry into the national phase

Ref document number: PI0818366

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100409